Shots:

• The approval is based on the PALM trial assessing Inmazeb vs Zmapp and remdesivir in 681 adult and pediatric patients including newborns of mothers who have tested positive for the infection. The study demonstrated 1EPs of mortality @28days (33.5% vs 51.3%) and 2EPs of reduction in days until the virus was undetectable in the bloodstream
• As per the agreement signed in Jul’2020- Regeneron will deliver a number of Inmazeb treatment doses for 6yrs. to the BARDA.
• Inmazeb is a triple antibody cocktail consisting of 3 mAbs (atoltivimab- maftivimab & odesivimab- 50 mg each /kg) that bind to different- non-overlapping epitopes on Zaire ebolavirus glycoprotein
  
    Ref: PR Newswire | Image: Stat